In type 2 diabetic patients, sitagliptin treatment reduced the molecular markers of inflammation as CRP and IL-6 in mononuclear cells (Makdissi et al., 2012), as well as circulating levels of TNF-α, IL-1β, IL-6, intracellular adhesion molecules and CRP (Tremblay et al., 2014). This evidence concerns the gene IL6 and type 2 diabetes mellitus.